Genfit S.a.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNFTF research report →
About the company
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver.
- CEO
- Pascal Prigent
- IPO
- 2014
- Employees
- 192
- HQ
- Loos, FR
Price Chart
- Market Cap
- $538.53M
- P/E
- -7.52
- P/S
- 9.60
- P/B
- -27.29
- EV/EBITDA
- -115.23
- Div Yield
- 0.00%
- Gross Margin
- 26.02%
- Op Margin
- -84.25%
- Net Margin
- -127.40%
- ROE
- -596.44%
- ROIC
- -41.41%
- Revenue
- $65.41M · -2.38%
- Net Income
- $-85,935,801 · -5802.44%
- EPS
- $-1.73 · -5866.67%
- Op Income
- $-58,898,931
- FCF YoY
- -287.76%
- 52W High
- $11.10
- 52W Low
- $3.28
- 50D MA
- $9.99
- 200D MA
- $7.28
- Beta
- 1.10
- Avg Volume
- 38
Get TickerSpark's AI analysis on GNFTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GNFTF coverage
Recent articles, reports, and earnings notes.
No research on GNFTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNFTF report →Similar companies
Peers in the same neighborhood.